公开(公告)号：US09808477B2

公开(公告)日：2017-11-07

申请号：US14848358

申请日：2015-09-09

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe Ma ,  Sen-ling Feng ,  Xiao-jun Yao ,  Zhong-wen Yuan ,  Liang Liu ,  Ying Xie

IPC: A61K31/352 ,  A61K31/337 ,  A61K45/06 ,  A61K31/704

CPC classification number: A61K31/366 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

公开(公告)号：US10265298B2

公开(公告)日：2019-04-23

申请号：US15682564

申请日：2017-08-22

Applicant: Macau University of Science and Technology

Inventor： Ying Xie ,  Liang Liu ,  Hua Zhou

IPC: A61K31/357 ,  A61K31/352 ,  A61K9/20 ,  A61P1/16 ,  A61K9/00

Abstract: One example embodiment relates to a method of increasing bioavailability of silybin in a person. The method includes providing silybin and a flavonoid to the person, wherein the flavonoid is tangeretin or baicalein. Another example embodiment relates to a method of treating chronic liver disease in a person by administering silybin and a flavonoid to the person to treat the chronic liver disease.

公开(公告)号：US20180289666A1

公开(公告)日：2018-10-11

申请号：US15481720

申请日：2017-04-07

Applicant: Macau University of Science and Technology

Inventor： Ying Xie ,  Liang Liu ,  Hua Zhou ,  Zhong-Wen Yuan ,  Yan-Fang Zheng ,  Sen-Ling Feng ,  Xiao-Hui Zeng ,  Hui Wang

IPC: A61K31/366

Abstract: A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome. Further provided is a method for reducing the risk of a cardiovascular disease in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism and a method for reducing hepatic abnormalities and reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by hepatic abnormalities. Still further provided is a method for reducing liver damages associated with the treatment of rheumatoid arthritis with a disease-modifying antirheumatic drug or a non-steroidal anti-inflammatory drug.

公开(公告)号：US09808439B2

公开(公告)日：2017-11-07

申请号：US14848360

申请日：2015-09-09

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe Ma ,  Sen-ling Feng ,  Xiao-jun Yao ,  Zhong-wen Yuan ,  Liang Liu ,  Ying Xie

IPC: A61K31/352 ,  A61K31/337 ,  A61K45/06 ,  A61K31/704

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is tangeretin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.